Article

Laparoscopic RP 'as efficient' as conventional surgery

Birmingham, United Kingdom-Laparoscopic radical prostatectomy is "as efficient" as conventional surgery in terms of pathological and biological results, according to mid-term follow-up of 940 French patients treated consecutively at the same institute-the largest single series of laparoscopic radical prostatectomies to date.

Related Videos
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Checkpoint Inhibitors for Treatment of NMIBC
Checkpoint Inhibitors for Treatment of NMIBC
Communication of Treatment Options for High-Risk NMIBC
Communication of Treatment Options for High-Risk NMIBC
Jason Hafron, MD, considers the future for AI in urology
Jason Hafron, MD, considers the future for AI in urology
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
3 experts are featured in this series.
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
3 experts are featured in this series.
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Related Content
blur image background of corridor in hospital or clinic image | Image Credit: @ whyframeshot - stock.adobe.com
April 4th 2025

UroLift may offer improved early recovery period vs Rezūm for BPH

Hannah Clarke
“The differences in patient experience between UroLift System and Rezūm, particularly in terms of early recovery, sexual function, and overall satisfaction, are key considerations for both clinicians and patients selecting a treatment path," says Mark Rochester, MD, FRCS.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC
April 3rd 2025

Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC

Mehmet Asim Bilen, MD Hannah Clarke
"The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Faceless view of senior man talking to doctor in bright light while taking notes on clipboard | Image Credit: © DragonImages - stock.adobe.com
April 3rd 2025

Kiran Sury, MD, on implementing ProACT for incontinence

Kiran Sury, MD
"In terms of making it a safe, highly reliable operation, if you're comfortable with slings and sphincters, you are very well positioned to learn this surger," says Kiran Sury, MD.
FDA grants 510(k) clearance to Glean Urodynamics System
April 2nd 2025

FDA grants 510(k) clearance to Glean Urodynamics System

Hannah Clarke
"Glean will enable patients to void naturally, without catheters in place. I believe this advance will yield a better test that mimics actual symptoms," says Bilal I. Chughtai, MD.
© 2025 MJH Life Sciences

All rights reserved.